Inhalation Sciences (ISAB) investor relations material

Executive summary

• Revenue and order intake surged year-over-year, driven by conversion of long-standing quotations and a strong order backlog from Q4 2025.

• Achieved Q1 2026 revenue of 4,147 tkr, surpassing total 2025 revenue.

• Signed new orders worth SEK 2.5 million in Q1 2026, including a major IRS order of 1.5 MSEK.

• Ongoing M&A process with PharmaVentures, aiming for conclusion before summer 2026.

• Strong customer return rate attributed to unique technology and effective communication.

Financial highlights

• Q1 2026 net revenue was 4,147 tkr, up from 809 tkr in Q1 2025.

• Operating result improved to -1,400 tkr from -2,241 tkr year-over-year.

• Order intake reached 2,420 tkr, up from 908 tkr in the prior year period.

• Pipeline of validated opportunities totals around SEK 20 million.

• Cash flow from operations was -1,245 tkr, unchanged from Q1 2025.

Outlook and guidance

• Several large opportunities and quotations in the pipeline, with efforts focused on converting them to orders.

• M&A process expected to conclude or clarify direction before summer 2026.

• Commercialization efforts expanding with new modules and services in development.

• Marketing campaigns expected to generate further leads and deals.